Axogen EVP receives 22,500 performance shares in stock award

Axogen executive Marc Began, EVP & General Counsel, acquired 22,500 shares of Axogen common stock on 12/04/2025 at a reported price of $0 per share.

Rhea-AI Filing Summary

Axogen executive Marc Began, EVP & General Counsel, acquired 22,500 shares of Axogen common stock on 12/04/2025 at a reported price of $0 per share. According to the explanation, these shares were issued upon the attainment of certain performance criteria, indicating a performance-based equity award rather than an open-market purchase. Following this transaction, Began beneficially owns 40,785 shares of Axogen common stock.

Insider Trade Summary

Grant/Award: 22,500 shares

Grant/Award 1 txn

Insider Began Marc A

Role EVP & General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	22,500	$0.00	$0.00

Holdings After Transaction: Common Stock — 40,785 shares (Direct)

Footnotes (1)

1. F1. This reflects the number of shares issued upon the attainment of certain performance criteria.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider stock transaction did Axogen (AXGN) report for Marc Began?

Axogen reported that Marc Began, its EVP & General Counsel, acquired 22,500 shares of Axogen common stock on 12/04/2025 at a price of $0 per share.

Why were the 22,500 Axogen (AXGN) shares issued to Marc Began?

The disclosure states that the 22,500 shares reflect the number of shares issued upon the attainment of certain performance criteria, indicating a performance-based equity award.

How many Axogen (AXGN) shares does Marc Began own after this award?

After the reported transaction, Marc Began beneficially owns 40,785 shares of Axogen common stock.

What is Marc Began’s role at Axogen (AXGN)?

Marc Began is identified as an Officer of Axogen with the title EVP & General Counsel.

Was the reported Axogen (AXGN) transaction in derivative securities?

No derivative securities transactions are shown in the excerpted Table II; the reported activity involves non-derivative common stock in Table I.

What type of security did Marc Began receive from Axogen (AXGN)?

Marc Began received Axogen common stock, with 22,500 shares acquired as noted in the non-derivative securities table.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/05/2025 - 04:56 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Began Marc A

(Last) (First) (Middle)

13631 PROGRESS BLVD.,

SUITE 400

(Street)

ALACHUA FL 32615

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Axogen, Inc. [ AXGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
12/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/04/2025		A		22,500(1)	A	$0	40,785	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This reflects the number of shares issued upon the attainment of certain performance criteria.

Remarks:

	/s/ Marc Began	12/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.